Adding the immunotherapy durvalumab (Imfinzi, AstraZeneca) to a standard chemotherapy regimen improves outcomes for people with resectable gastric or gastroesophageal junction cancer, per results of the phase 3 MATTERHORN trial presented at the 2025 ASCO Annual Meeting, in Chicago.
“I’m pleased to report that MATTERHORN met its primary end point of event-free survival [EFS],” said principal investigator Yelena Janjigian, MD, the chief of gastrointestinal medical oncology at